NEW YORK (GenomeWeb News) – A new center in Ontario, Canada focused on pharmacogenetic applications for addiction and mental health has been established with a C$19 million (US$19.1 million) investment.

The center, called the Tanenbaum Centre for Pharmacogenetics, is a collaboration between businessman Lawrence Tanenbaum, the Ontario government, and the Centre for Addiction and Mental Health (CAMH) and will support research to accelerate the time it takes to get genetic information to physicians and patients in Ontario.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: rare variants linked to bleeding disorder, comparison of whole-exome and whole-genome sequencing, and more.

George Church tells The Sunday Times that his group has inserted some woolly mammoth genes into elephant cells.

A Scientific Reports editor resigns over a new policy at the journal allowing researchers to pay to fast track the peer review of their manuscripts, and poll.

The National Cancer Institute's Harold Varmus discusses the state of cancer research with the New York Times.